홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
NGNE
#2510
Neurogene, Inc. Common Stock
23.490
0
+21.87%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+21.87%
월간 변동
+18.04%
6달 변화
-20.16%
년간 변동율
-20.16%
이전 종가
19.275
0
Open
23.490
0
Bid
Ask
Low
23.490
0
High
23.490
0
양
39
마켓
주식
헬스케어
NGNE
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
14.85 M
14.93 M
14.26 M
14.27 M
15.49 M
—
Valuation ratios
Enterprise value
556.67 M
204.7 M
96.24 M
154.55 M
197.43 M
652.93 M
Price to earnings ratio
-11.03
-5.34
-2.68
-3.46
-4.23
-15.71
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
6.2
5.69
3.05
3.9
4.52
17.16
Price to book ratio
0.62
1.29
0.24
0.28
0.3
2.12
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.12
0.06
0.07
0.07
0.07
0.28
Return on equity %
0.15
0.06
0.08
0.08
0.08
0.3
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.09
20.84
21.03
18.07
18.39
78.33
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.92
1
0.99
0.92
0.92
3.83
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
8.2
17.78
13.94
13.04
12.54
57.3
Net current asset value per share
8.47
17.98
14.12
13.25
12.78
58.13
Tangible book value per share
8.11
17.67
13.9
12.98
12.54
57.09
Working capital per share
7.54
17.12
13.45
12.52
12.08
55.17
Book value per share
8.11
17.67
13.9
12.98
12.54
57.09
뉴스
Netflix, Dell among market cap stock movers on Friday
Why Is Neurogene Stock Skyrocketing Friday? - Neurogene (NASDAQ:NGNE)
뉴로진, FDA 혁신 치료제 지정에 30% 급등
Neurogene stock surges 30% on FDA breakthrough therapy status
FDA grants breakthrough therapy status to Neurogene’s Rett drug
스티펠, 뉴로진(Neurogene) 주식에 ’매수’ 등급 재확인
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Neurogene doses multiple patients in Rett syndrome gene therapy trial
테이샤 유전자 치료제, Citizens "시장 수익률 상회" 등급 재확인
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE)